

Electronic Proof

***** **ATTENTION** *****

The format and/or verbiage of the SEC cover may have been modified to conform to SEC supplied templates and/or SEC rules and regulations. Furthermore, an exhibit index may have been added to the main document to comply with SEC Regulation S-T §232.102(d).

* * * **CLIENT QUERY** * * *

PLEASE ADVISE

This proof may not fit on letter-sized (8.5 x 11 inch) paper. If copy is cut off, please print to larger, e.g., legal-sized (8.5 x 14 inch) paper.

Accuracy of proof is guaranteed ONLY if printed to a PostScript printer using the correct PostScript driver for that printer make and model.

C88123.SUB



<SUBMISSION>
<TYPE> 25
<DOCUMENT-COUNT> 1
<LIVE>
<FILER-CIK> 0001301357
<FILER-CCC> #####
<CONTACT-NAME> Pure Compliance
<CONTACT-PHONE-NUMBER> 1-866-444-6820
<SROS> NASD
<NOTIFY-INTERNET> David.McGarvey@pharmaxis.com.au
<NOTIFY-INTERNET> pure.compliance@bowne.com
<NOTIFY-INTERNET> lisette.navas@bowne.com



<DOCUMENT>
<TYPE> 25
<FILENAME> c88123e25.htm
<DESCRIPTION> Form 25
<TEXT>

[E/O]

CRC: 16102
EDGAR 2

BPC C88123 001.00.00.00 0/1


**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 25

**NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Commission File Number **000-51505**

Pharmaxis Ltd

NASDAQ Global Market

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

2/10 Rodborough Road, Frenchs Forest, NSW 2086, Australia

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Ordinary shares in the form of American Depositary Shares evidenced by American Depositary Receipts

(Description of class of securities)

Place an X in the box to designate the rule provision relied upon to strike the close of securities from listing and registration:

- 17CFR 240.12d2-2(a)(1)
- 17CFR 240.12d2-2(a)(2)
- 17CFR 240.12d2-2(a)(3)
- 17CFR 240.12d2-2(a)(4)
- Pursuant to 17 CFR240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.
- Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Pharmaxis Ltd certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

July 23, 2009

By: Alan Roberston

Chief Executive Officer

Date

Name

Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

SEC 1654(03-06) **Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number**